Cargando…

Comparison of 10 noninvasive models for predicting overall survival in patients with intermediate-stage hepatocellular carcinoma

Intermediate-stage hepatocellular carcinoma (HCC) is heterogeneous in terms of tumor size, number, and effects on liver function. Various noninvasive models have been proposed to assess functional hepatic reserve or fibrosis severity in patients with HCC. This study assessed the feasibility of 10 no...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Wei-Fan, Chang, Kai-Chih, Chen, Te-Hong, Lin, Chien-Hung, Lin, Ying-Chun, Tsai, Ming-Hung, Chen, Pei-Yu, Wang, Hung-Wei, Chu, Chia-Sheng, Peng, Cheng-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376350/
https://www.ncbi.nlm.nih.gov/pubmed/34414987
http://dx.doi.org/10.1097/MD.0000000000027000
_version_ 1783740476090744832
author Hsu, Wei-Fan
Chang, Kai-Chih
Chen, Te-Hong
Lin, Chien-Hung
Lin, Ying-Chun
Tsai, Ming-Hung
Chen, Pei-Yu
Wang, Hung-Wei
Chu, Chia-Sheng
Peng, Cheng-Yuan
author_facet Hsu, Wei-Fan
Chang, Kai-Chih
Chen, Te-Hong
Lin, Chien-Hung
Lin, Ying-Chun
Tsai, Ming-Hung
Chen, Pei-Yu
Wang, Hung-Wei
Chu, Chia-Sheng
Peng, Cheng-Yuan
author_sort Hsu, Wei-Fan
collection PubMed
description Intermediate-stage hepatocellular carcinoma (HCC) is heterogeneous in terms of tumor size, number, and effects on liver function. Various noninvasive models have been proposed to assess functional hepatic reserve or fibrosis severity in patients with HCC. This study assessed the feasibility of 10 noninvasive models and compared their prognostic ability for patients with intermediate-stage HCC. This study retrospectively enrolled 493 patients with intermediate-stage HCC who received treatment at China Medical University Hospital from January 2012 to November 2018. Demographic data, clinical features, and factors associated with overall survival (OS) were recorded at baseline. Receiver-operating characteristic curve analysis and the DeLong method were respectively employed to evaluate and compare the models’ OS prediction performance. Of the 493 patients, 373 (75.7%) were male, and 275 (55.8%) had liver cirrhosis (LC). The median age was 64 years (interquartile range: 55–72). Most patients had tumor volume ≤50% (n = 424, 86.0%), and the maximum tumor size was 6.0 (4.0–8.5) cm. The median α-fetoprotein was 36.25 (6.13–552.91) ng/mL. The patients underwent transarterial chemoembolization (TACE, n = 349) or surgery (n = 144). The median follow-up period was 26.07 (9.77–48.27) months. Across the 10 models, the albumin–bilirubin (ALBI) score had the highest area under the receiver operating characteristic curve (AUROC) (0.644, 95% confidence interval: 0.595–0.693) in all patients. In subgroup analyses, the Lok index, platelet–albumin–bilirubin score, ALBI score, and Lok index had the highest AUROC values in patients without cirrhosis, with cirrhosis, undergoing TACE, and undergoing surgery, respectively. Multivariate Cox regression analysis revealed that independent predictors of longer OS were ALBI grade 1 in all patients, patients with LC, and patients undergoing TACE and Lok index grade 1 in patients without LC and patients undergoing surgery. Among the 10 noninvasive models, ALBI score exhibited the highest diagnostic value in predicting OS for all patients, patients with cirrhosis, and those undergoing TACE, and Lok index grade exhibited the highest diagnostic value in predicting OS in patients without cirrhosis and those undergoing surgery.
format Online
Article
Text
id pubmed-8376350
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-83763502021-08-21 Comparison of 10 noninvasive models for predicting overall survival in patients with intermediate-stage hepatocellular carcinoma Hsu, Wei-Fan Chang, Kai-Chih Chen, Te-Hong Lin, Chien-Hung Lin, Ying-Chun Tsai, Ming-Hung Chen, Pei-Yu Wang, Hung-Wei Chu, Chia-Sheng Peng, Cheng-Yuan Medicine (Baltimore) 4500 Intermediate-stage hepatocellular carcinoma (HCC) is heterogeneous in terms of tumor size, number, and effects on liver function. Various noninvasive models have been proposed to assess functional hepatic reserve or fibrosis severity in patients with HCC. This study assessed the feasibility of 10 noninvasive models and compared their prognostic ability for patients with intermediate-stage HCC. This study retrospectively enrolled 493 patients with intermediate-stage HCC who received treatment at China Medical University Hospital from January 2012 to November 2018. Demographic data, clinical features, and factors associated with overall survival (OS) were recorded at baseline. Receiver-operating characteristic curve analysis and the DeLong method were respectively employed to evaluate and compare the models’ OS prediction performance. Of the 493 patients, 373 (75.7%) were male, and 275 (55.8%) had liver cirrhosis (LC). The median age was 64 years (interquartile range: 55–72). Most patients had tumor volume ≤50% (n = 424, 86.0%), and the maximum tumor size was 6.0 (4.0–8.5) cm. The median α-fetoprotein was 36.25 (6.13–552.91) ng/mL. The patients underwent transarterial chemoembolization (TACE, n = 349) or surgery (n = 144). The median follow-up period was 26.07 (9.77–48.27) months. Across the 10 models, the albumin–bilirubin (ALBI) score had the highest area under the receiver operating characteristic curve (AUROC) (0.644, 95% confidence interval: 0.595–0.693) in all patients. In subgroup analyses, the Lok index, platelet–albumin–bilirubin score, ALBI score, and Lok index had the highest AUROC values in patients without cirrhosis, with cirrhosis, undergoing TACE, and undergoing surgery, respectively. Multivariate Cox regression analysis revealed that independent predictors of longer OS were ALBI grade 1 in all patients, patients with LC, and patients undergoing TACE and Lok index grade 1 in patients without LC and patients undergoing surgery. Among the 10 noninvasive models, ALBI score exhibited the highest diagnostic value in predicting OS for all patients, patients with cirrhosis, and those undergoing TACE, and Lok index grade exhibited the highest diagnostic value in predicting OS in patients without cirrhosis and those undergoing surgery. Lippincott Williams & Wilkins 2021-08-20 /pmc/articles/PMC8376350/ /pubmed/34414987 http://dx.doi.org/10.1097/MD.0000000000027000 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle 4500
Hsu, Wei-Fan
Chang, Kai-Chih
Chen, Te-Hong
Lin, Chien-Hung
Lin, Ying-Chun
Tsai, Ming-Hung
Chen, Pei-Yu
Wang, Hung-Wei
Chu, Chia-Sheng
Peng, Cheng-Yuan
Comparison of 10 noninvasive models for predicting overall survival in patients with intermediate-stage hepatocellular carcinoma
title Comparison of 10 noninvasive models for predicting overall survival in patients with intermediate-stage hepatocellular carcinoma
title_full Comparison of 10 noninvasive models for predicting overall survival in patients with intermediate-stage hepatocellular carcinoma
title_fullStr Comparison of 10 noninvasive models for predicting overall survival in patients with intermediate-stage hepatocellular carcinoma
title_full_unstemmed Comparison of 10 noninvasive models for predicting overall survival in patients with intermediate-stage hepatocellular carcinoma
title_short Comparison of 10 noninvasive models for predicting overall survival in patients with intermediate-stage hepatocellular carcinoma
title_sort comparison of 10 noninvasive models for predicting overall survival in patients with intermediate-stage hepatocellular carcinoma
topic 4500
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8376350/
https://www.ncbi.nlm.nih.gov/pubmed/34414987
http://dx.doi.org/10.1097/MD.0000000000027000
work_keys_str_mv AT hsuweifan comparisonof10noninvasivemodelsforpredictingoverallsurvivalinpatientswithintermediatestagehepatocellularcarcinoma
AT changkaichih comparisonof10noninvasivemodelsforpredictingoverallsurvivalinpatientswithintermediatestagehepatocellularcarcinoma
AT chentehong comparisonof10noninvasivemodelsforpredictingoverallsurvivalinpatientswithintermediatestagehepatocellularcarcinoma
AT linchienhung comparisonof10noninvasivemodelsforpredictingoverallsurvivalinpatientswithintermediatestagehepatocellularcarcinoma
AT linyingchun comparisonof10noninvasivemodelsforpredictingoverallsurvivalinpatientswithintermediatestagehepatocellularcarcinoma
AT tsaiminghung comparisonof10noninvasivemodelsforpredictingoverallsurvivalinpatientswithintermediatestagehepatocellularcarcinoma
AT chenpeiyu comparisonof10noninvasivemodelsforpredictingoverallsurvivalinpatientswithintermediatestagehepatocellularcarcinoma
AT wanghungwei comparisonof10noninvasivemodelsforpredictingoverallsurvivalinpatientswithintermediatestagehepatocellularcarcinoma
AT chuchiasheng comparisonof10noninvasivemodelsforpredictingoverallsurvivalinpatientswithintermediatestagehepatocellularcarcinoma
AT pengchengyuan comparisonof10noninvasivemodelsforpredictingoverallsurvivalinpatientswithintermediatestagehepatocellularcarcinoma